IP Library › Assignment 068938/0906
Patent Assignment
Reel/Frame 068938/0906

Security Interest

Recorded: 2024-09-11 Pages: 50
Assignor
BIOXCEL THERAPEUTICS, INC.
Executed: 2024-09-09
Assignee
OAKTREE FUND ADMINISTRATION, LLC
333 S. GRAND AVENUE, 28TH FL., LOS ANGELES, CALIFORNIA, 90071
Covered Properties (120)
Approach for Treatment of Cancer via Immunomodulation by Using Talabostat
Application: 15/467,781 →
Publication: US 2017/0266280
Film Formulations Containing Dexmedetomidine and Methods of Producing Them
Application: 16/453,679 →
Publication: US 2020/0000717
Use of Sublingual Dexmedetomidine for the Treatment of Agitation
Application: 16/474,882 →
Publication: US 2019/0365715
Predictive and Diagnostic Methods for Prostate Cancer
Application: 16/476,420 →
Publication: US 2021/0355541
Film Formulations Containing Dexmedetomidine and Methods of Producing Them
Application: 16/931,630 →
Publication: US 2020/0345635
Film Formulations Containing Dexmedetomidine and Methods of Producing Them
Application: 17/103,013 →
Publication: US 2021/0077388
Methods for Treating Agitation Using Dexmedetomidine Hydrochloride
Application: 17/254,982 →
Publication: US 2021/0267944
Combination Therapies for Treating Disease Using an Innate Immunity Modifier and an OX40 Agonist
Application: 17/311,770 →
Publication: US 2022/0025061
Novel Approach for Treatment of Cancer Using Immunomodulation
Application: 17/312,368 →
Publication: US 2022/0089733
Use of Sublingual Dexmedetomidine for the Treatment of Agitation
Application: 17/496,470 →
Publication: US 2022/0031663
Film Formulations Containing Dexmedetomidine and Methods of Producing Them
Application: 17/560,392 →
Publication: US 2022/0110864
Film Formulations Containing Dexmedetomidine and Methods of Producing Them
Application: 17/560,423 →
Publication: US 2022/0160629
Dexmedetomidine Treatment Regimens
Application: 17/568,474 →
Publication: US 2022/0226288
Film Formulations Containing Dexmedetomidine and Methods of Producing Them
Application: 17/579,914 →
Publication: US 2022/0142918
Non-Sedating Dexmedetomidine Treatment Regimens
Application: 17/628,021 →
Publication: US 2024/0024288
Treatment of Sarcoma Using Immunomodulation
Application: 17/674,371 →
Publication: US 2022/0257759
Systems and Methods of Using Machine Learning to Detect and Predict Emergence of Agitation Based on Sympathetic Nervous System Activities
Application: 17/698,407 →
Publication: US 2022/0202373
Treatment Regimen for Cancer Using Immunomodulation
Application: 17/797,388 →
Publication: US 2023/0338402
Systems and Methods for Detection and Prevention of Emergence of Agitation
Application: 17/886,231 →
Publication: US 2022/0395222
Use of Sublingual Dexmedetomidine for the Treatment of Agitation
Application: 17/990,312 →
Publication: US 2023/0081503
Use of Sublingual Dexmedetomidine for the Treatment of Agitation
Application: 17/990,332 →
Publication: US 2023/0093109
Non-Sedating Dexmedetomidine Treatment Regimens
Application: 17/993,422 →
Publication: US 2023/0118091
Treatment of Bipolar Disorders and Psychosis Using Dexmedetomidine Hydrochloride
Application: 18/030,405 →
Publication: US 2024/0024289
Film Formulations Containing Dexmedetomidine and Methods of Producing Them
Application: 18/085,263 →
Publication: US 2023/0140624
Use of Sublingual Dexmedetomidine for the Treatment of Agitation
Application: 18/124,943 →
Publication: US 2023/0218580
Non-Sedating Dexmedetomidine Treatment Regimens
Application: 18/153,870 →
Non-Sedating Dexmedetomidine Treatment Regimens
Application: 18/176,296 →
Publication: US 2024/0245650
Non-Sedating Dexmedetomidine Treatment Regimens
Application: 18/189,073 →
Non-Sedating Dexmedetomidine Treatment Regimens
Application: 18/216,890 →
Publication: US 2023/0338339
Methods and Compositions for Treating Agitation
Application: 18/278,786 →
Publication: US 2024/0139169
Non-Sedating Dexmedetomidine Treatment Regimens
Application: 18/430,003 →
Publication: US 2024/0173299
Use of Sublingual Dexmedetomidine for the Treatment of Agitation
Application: 18/436,589 →
Publication: US 2024/0252470
Non-Sedating Dexmedetomidine Treatment Regimens
Application: 18/443,689 →
Publication: US 2024/0197684
Film Formulations Containing Dexmedetomidine and Methods of Producing Them
Application: 18/448,640 →
Publication: US 2023/0381099
Non-Sedating Dexmedetomidine Treatment Regimens
Application: 18/526,686 →
Publication: US 2024/0252471
Methods for Treating Depressive States
Application: 18/574,404 →
Non-Sedating Dexmedetomidine Treatment Regimens
Application: 18/600,419 →
Publication: US 2024/0277669
Non-Sedating Dexmedetomidine Treatment Regimens
Application: 18/600,431 →
Publication: US 2024/0245651
Prevention or Treatment of Sleep Disorders Using Dexmedetomidine Formulation
Application: 18/634,242 →
Publication: US 2025/0099430
Novel Approach for Treatment of Cancer Using Immunomodulation
Application: 18/802,908 →
Publication: US 2025/0213681
Methods and Compositions for Treating Agitation
Application: 18/812,515 →
Publication: US 2025/0228833
Prevention or treatment of sleep disorders using dexmedetomidine sublingual formulation
Application: 62/064,205 →
Novel approach for treatment of cancer using immunomodulation
Application: 62/193,348 →
Novel approach for treatment of cancer using immunomodulation
Application: 62/204,495 →
Method of Treating Agitation Using Dexmedetomidine
Application: 62/441,164 →
Predictive and Diagnostic Methods for Prostate Cancer
Application: 62/443,831 →
Use of sublingual Dexmedetomidine for treatment of agitation
Application: 62/471,393 →
Predictive and Diagnostic Methods for Cancer
Application: 62/473,507 →
Use of Dexmedetomidine for Treatment of Agitation and Aggression
Application: 62/542,323 →
Predictive and Diagnostic Methods for Cancer
Application: 62/561,218 →
Thin Film Formulations Containing Dexmedetomidine and Methods of Producing Them
Application: 62/690,407 →
Thin Film Formulations Containing Dexmedetomidine and Methods of Producing Them
Application: 62/693,726 →
Intravenous Administration of Dexmedetomidine to Treat Agitation and Induce a Mild Sedative Effect
Application: 62/767,422 →
Combination Therapies for Treating Disease Using an Innate Immunity Modifier and an Immune Checkpoint Inhibitor, and an OX40 Agonist
Application: 62/777,350 →
Novel Approach for Treatment of Cancer Using Immunomodulation
Application: 62/777,352 →
Intravenous Administration of Dexmedetomidine to Treat Agitation and Induce a Mild Sedative Effect
Application: 62/787,649 →
Combination Therapies for Treating Disease Using an Innate Immunity Modifier and an OX40 Agonist
Application: 62/790,569 →
Intravenous Administration of Dexmedetomidine to Treat Agitation or Hyper-Arousal
Application: 62/798,842 →
Thin Film Formulations Containing Dexmedetomidine and Methods of Producing Them
Application: 62/849,747 →
Film Formulations Containing Dexmedetomidine and Methods of Producing Them
Application: 62/876,371 →
Film Formulations Containing Dexmedetomidine and Methods of Producing Them
Application: 62/877,056 →
Prevention of Emergence of Agitation
Application: 62/901,955 →
Novel Approach for Treatment of Cancer Using Immunomodulation
Application: 62/924,429 →
Non-Sedating Dexmedetomidine Treatment Regimens
Application: 62/943,022 →
Film Formulations Containing Dexmedetomidine and Methods of Producing Them
Application: 62/963,769 →
Film Formulations Containing Dexmedetomidine and Methods of Producing Them
Application: 62/970,411 →
Novel Approach for Treatment of Cancer Using Immunomodulation
Application: 62/971,548 →
Prevention of Emergence of Agitation
Application: 62/976,685 →
Film Formulations Containing Dexmedetomidine and Methods of Producing Them
Application: 62/977,554 →
Novel Approach for Treatment of Cancer Using Immunomodulation
Application: 63/029,066 →
Film Formulations Containing Dexmedetomidine and Methods of Producing Them
Application: 63/037,759 →
Novel Approach for Treatment of Cancer Using Immunomodulation
Application: 63/069,405 →
Novel Approach for Treatment of Cancer Using Immunomodulation
Application: 63/088,038 →
Treatment of Mania and Psychosis Using Dexmedetomidine Hydrochloride
Application: 63/089,135 →
Novel Approach for Treatment of Cancer Using Immunomodulation
Application: 63/092,039 →
Novel Approach for Treatment of Cancer Using Immunomodulation
Application: 63/105,679 →
Novel Approach for Treatment of Cancer Using Immunomodulation
Application: 63/107,053 →
Dexmedetomidine Treatment Regimens
Application: 63/133,593 →
Novel Approach for Treatment of Cancer Using Immunomodulation
Application: 63/139,594 →
Novel Approach for Treatment of Cancer Using Immunomodulation
Application: 63/150,493 →
Methods and Compositions for Treating Agitation
Application: 63/154,281 →
Dexmedetomidine Treatment Regimens
Application: 63/156,703 →
Dexmedetomidine Treatment Regimens
Application: 63/168,995 →
Dexmedetomidine Treatment Regimens
Application: 63/180,284 →
Methods for Treating Depressive States
Application: 63/218,031 →
Dexmedetomidine Treatment Regimens
Application: 63/218,965 →
Methods for Treating Depressive States
Application: 63/247,122 →
Stable Tablet Formulations of Talabostat
Application: 63/317,726 →
Methods and Compositions for Treating and Preventing Acute Stress Disorder
Application: 63/402,855 →
Methods for Treating Agitation in Community Settings
Application: 63/405,452 →
Predictive Biomarkers for Responsiveness to Dpp Inhibitors in Cancers
Application: 63/422,100 →
Treatment Regimen for Treating Cancers
Application: 63/426,019 →
Novel Approach for Treatment of Cancer Using Immunomodulation
Application: 63/439,752 →
Methods for Treating Depressive States
Application: 63/495,070 →
Methods for Treating Depressive States
Application: 63/502,396 →
Dexmedetomidine Treatment Regimens
Application: 63/510,101 →
Dexmedetomidine Treatment Regimens
Application: 63/523,098 →
Combination of Latrepirdine and a Pharmacokinetic Stabilizer
Application: 63/608,676 →
Prevention or Treatment of Sleep Disorders Using Dexmedetomidine Formulation
A Novel Approach for Treatment of Cancer Using Immunomodulation
Use of Sublingual Dexmedetomidine for the Treatment of Agitation
Predictive and Diagnostic Methods for Prostate Cancer
Combination Therapies for Treating Disease Using an Innate Immunity Modifier and an OX40 Agonist
Novel Approach for Treatment of Cancer Using Immunomodulation
Non-Sedating Dexmedetomidine Treatment Regimens
Systems and Methods for Detection and Prevention of Emergence of Agitation
Treatment Regimen for Cancer Using Immunomodulation
Systems and Methods for Detection and Prevention of Emergence of Agitation
Treatment of Bipolar Disorders and Psychosis Using Dexmedetomidine Hydrochloride
Dexmedetomidine Treatment Regimens
Methods and Compositions for Treating Agitation
Methods for Treating Depressive States
Methods and Compositions for Treating Acute Stress Disorder
Stable Formulations of Talabostat
Methods for Treating Agitation in Community Settings
Predictive Biomarkers for Responsiveness to Dpp Inhibitors in Cancers
Treatment Regimen for Treating Cancers
Novel Approach for Treatment of Cancer Using Immunomodulation
Methods for Treating Depressive States
Dexmedetomidine Treatment Regimens
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest May 18, 2017
From: RASTELLI, LUCA; SAPRA, APARNA KATOCH; MEHTA, VIMAL
To: BIOXCEL CORPORATION
Reel/Frame 042493/0776 →
Assignment of Assignor's Interest Nov 17, 2017
From: BIOXCEL CORPORATION
To: BIOXCEL THERAPEUTICS, INC.
Reel/Frame 044482/0489 →
Assignment of Assignor's Interest Jul 8, 2019
From: NANDABALAN, KRISHNAN; RASTELLI, LUCA
To: BIOXCEL THERAPEUTICS, INC.
Reel/Frame 049689/0674 →
Assignment of Assignor's Interest Aug 12, 2019
From: E.Z. BIOXCEL SOLUTIONS PVT. LTD.
To: BIOXCEL THERAPEUTICS, INC.
Reel/Frame 050021/0158 →
Assignment of Assignor's Interest Aug 12, 2019
From: BARNHART, SCOTT DAVID
To: ARX, LLC
Reel/Frame 050021/0186 →
Assignment of Assignor's Interest Aug 12, 2019
From: HANLEY, DAVID CHRISTIAN; YOCCA, FRANK; LATHIA, CHETAN DALPATBHAI
To: BIOXCEL THERAPEUTICS, INC.
Reel/Frame 050021/0123 →
Assignment of Assignor's Interest Aug 12, 2019
From: KAKUMANU, VASUKUMAR
To: E.Z. BIOXCEL SOLUTIONS PVT. LTD.
Reel/Frame 050021/0151 →
Assignment of Assignor's Interest Nov 11, 2019
From: E. Z. BIOXCEL SOLUTIONS PVT. LTD.
To: BIOXCEL THERAPEUTICS, INC.
Reel/Frame 050970/0333 →
Assignment of Assignor's Interest Nov 11, 2019
From: NANDABALAN, KRISHNAN
To: BIOXCEL CORPORATION
Reel/Frame 050970/0190 →
Assignment of Assignor's Interest Nov 11, 2019
From: BIOXCEL CORPORATION
To: BIOXCEL THERAPEUTICS, INC.
Reel/Frame 050970/0209 →
Assignment of Assignor's Interest Nov 11, 2019
From: YOCCA, FRANK
To: BIOXCEL THERAPEUTICS, INC.
Reel/Frame 050970/0177 →
Assignment of Assignor's Interest Nov 11, 2019
From: SHARMA, SAMEER
To: E.Z. BIOXCEL SOLUTIONS PVT. LTD.
Reel/Frame 050970/0327 →
Assignment of Assignor's Interest Jul 17, 2020
From: HANLEY, DAVID CHRISTIAN; YOCCA, FRANK; LATHIA, CHETAN DALPATBHAI
To: BIOXCEL THERAPEUTICS, INC.
Reel/Frame 053242/0187 →
Assignment of Assignor's Interest Jul 17, 2020
From: E.Z. BIOXCEL SOLUTIONS PVT. LTD.
To: BIOXCEL THERAPEUTICS, INC.
Reel/Frame 053242/0808 →
Assignment of Assignor's Interest Jul 17, 2020
From: BARNHART, SCOTT DAVID
To: ARX, LLC
Reel/Frame 053242/0257 →
Assignment of Assignor's Interest Jul 17, 2020
From: KAKUMANU, VASUKUMAR
To: E.Z. BIOXCEL SOLUTIONS PVT. LTD.
Reel/Frame 053242/0768 →
Assignment of Assignor's Interest Nov 24, 2020
From: BARNHART, SCOTT DAVID
To: ARX, LLC
Reel/Frame 054460/0460 →
Assignment of Assignor's Interest Nov 24, 2020
From: E.Z. BIOXCEL SOLUTIONS PVT. LTD.
To: BIOXCEL THERAPEUTICS, INC.
Reel/Frame 054460/0414 →
Assignment of Assignor's Interest Nov 24, 2020
From: KAKUMANU, VASUKUMAR
To: E.Z. BIOXCEL SOLUTIONS PVT. LTD.
Reel/Frame 054514/0629 →
Assignment of Assignor's Interest Nov 24, 2020
From: HANLEY, DAVID CHRISTIAN; YOCCA, FRANK; LATHIA, CHETAN DALPATBHAI
To: BIOXCEL THERAPEUTICS, INC.
Reel/Frame 054460/0332 →
Assignment of Assignor's Interest Dec 22, 2020
From: YOCCA, FRANK D.; DE VIVO, MICHAEL
To: BIOXCEL THERAPEUTICS, INC.
Reel/Frame 054721/0124 →
Corrective Assignment to Correct the Signature Page by Assignee (Correcting Assignee Name to Ez Bioxcel Solutions Pvt. Ltd. Rather Than Bioxcel Therapeutics, Inc. Previously Recorded on Reel 050021 Frame 0151. Assignor(S) Hereby Confirms the Correct Assignee Name for Signature Is Ez Bioxcel Solutions Pvt. Ltd. Jan 12, 2021
From: KAKUMANU, VASUKUMAR
To: E.Z. BIOXCEL SOLUTIONS PVT. LTD.
Reel/Frame 054976/0212 →
Assignment of Assignor's Interest Jun 8, 2021
From: GUPTA, SNIGDHA
To: E.Z. BIOXCEL SOLUTIONS PVT. LTD.
Reel/Frame 056472/0441 →
Assignment of Assignor's Interest Jun 8, 2021
From: E.Z. BIOXCEL SOLUTIONS PVT. LTD.
To: BIOXCEL THERAPEUTICS, INC.
Reel/Frame 056472/0474 →
Assignment of Assignor's Interest Jun 8, 2021
From: MEHTA, VIMAL D.; RASTELLI, LUCA; MACDOUGALL, JOHN
To: BIOXCEL THERAPEUTICS, INC.
Reel/Frame 056472/0398 →